10/25
09:28 am
acst
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. [Canadian Business Journal (Canada)]
Medium
Report
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. [Canadian Business Journal (Canada)]
10/25
09:00 am
acst
Acasti Pharma changes name to Grace Therapeutics [Seeking Alpha]
Medium
Report
Acasti Pharma changes name to Grace Therapeutics [Seeking Alpha]
10/25
08:00 am
acst
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
Medium
Report
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
9/26
02:11 pm
acst
Acasti Pharma Inc. (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Neutral
Report
Acasti Pharma Inc. (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
9/26
12:16 pm
acst
Acasti Pharma Inc. (NASDAQ: ACST) had its price target raised by analysts at Craig Hallum from $6.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Acasti Pharma Inc. (NASDAQ: ACST) had its price target raised by analysts at Craig Hallum from $6.00 to $8.00. They now have a "buy" rating on the stock.
9/25
07:30 am
acst
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
High
Report
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
9/12
08:00 am
acst
Acasti to Present at the Life Sciences Investor Forum
Medium
Report
Acasti to Present at the Life Sciences Investor Forum
9/5
10:35 am
acst
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
8/9
08:00 am
acst
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
Medium
Report
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update